Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Masimo Corporation
  6. Summary
    MASI   US5747951003

MASIMO CORPORATION

(MASI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/02/2021 12/03/2021 12/06/2021 12/07/2021 12/08/2021 Date
281.53(c) 276.97(c) 280.49(c) 282.98(c) 286.47(c) Last
188 787 163 707 237 948 194 979 152 067 Volume
+2.35% -1.62% +1.27% +0.89% +1.23% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 232 M - -
Net income 2021 224 M - -
Net cash position 2021 794 M - -
P/E ratio 2021 74,0x
Yield 2021 -
Sales 2022 1 349 M - -
Net income 2022 256 M - -
Net cash position 2022 1 196 M - -
P/E ratio 2022 65,4x
Yield 2022 -
Capitalization 15 819 M 15 819 M -
EV / Sales 2021 12,2x
EV / Sales 2022 10,8x
Nbr of Employees 2 000
Free-Float 70,7%
More Financials
Company
Masimo Corporation is a global medical technology company that develops, manufactures, and markets noninvasive technologies and hospital automation solutions. Its patient monitoring solution that incorporates a monitor or circuit board, single-patient use or reusable sensors, software and cables. The CompanyÔÇÖs main products include Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings... 
More about the company
Ratings of Masimo Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about MASIMO CORPORATION
12/08INSIDER SELL : Masimo
MT
11/29Masimo Rad-G« Helps Clinicians Identify Pediatric Pneumonia in Large Field Trial in Ind..
BU
11/29Masimo Corporation Rad-G? Helps Clinicians Identify Pediatric Pneumonia in Large Field ..
CI
11/23Masimo to Present in Piper Sandler 33rd Annual Healthcare Conference
BU
11/22INSIDER SELL : Masimo
MT
11/16INSIDER SELL : Masimo
MT
11/15Piper Sandler Adjusts Masimo's Price Target to $330 From $320, Reiterates Overweight Ra..
MT
11/15New Study Finds That Use of Masimo SedLine« PSi and DSA May Significantly Reduce Postop..
BU
11/11Masimo to Present in Stifel 2021 Virtual Healthcare Conference
BU
11/08INSIDER SELL : Masimo
MT
11/08Masimo Root« with a Multimodal Brain Monitoring Algorithm May Improve Postoperative Neu..
BU
11/08Masimo Announces Findings of Prospective Study Published in Frontiers in Aging Neurosci..
CI
11/01Masimo Launches Dual SET« Pulse Oximetry
BU
11/01Masimo Launches Dual SET? Pulse Oximetry
CI
10/28UBS Lifts Masimo's Price Target to $325 From $300, Reiterates Buy Rating
MT
More news
News in other languages on MASIMO CORPORATION
11/30Masimo Rad-G« ayuda al personal clínico a identificar la neumonía pediátrica en un gran..
11/30Masimo Rad-G« aide les cliniciens à identifier la pneumonie pédiatrique dans un essai s..
11/30Masimo Rad-G« hilft Ärzten, pädiatrische Pneumonie in einem großen Feldversuch in Indie..
11/22VENTE D'INITIÉS : Masimo
11/17Une nouvelle étude révèle que l'utilisation des indices PSi et DSA Masimo SedLine« peut..
More news
Analyst Recommendations on MASIMO CORPORATION
More recommendations
Chart MASIMO CORPORATION
Duration : Period :
Masimo Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MASIMO CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 286,47 $
Average target price 301,33 $
Spread / Average Target 5,19%
EPS Revisions
Managers and Directors
Joe E. Kiani Chairman & Chief Executive Officer
Micah Young Chief Financial Officer & Executive Vice President
Yongsam Lee Chief Information Officer & Executive VP
Anand Sampath Executive VP-Operations & Clinical Research
Jon Curtis Coleman President-Worldwide Sales & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
MASIMO CORPORATION6.74%15 819
GETINGE AB106.19%11 824
PENUMBRA, INC.49.47%9 559
NOVOCURE LIMITED-48.02%9 338
SHOCKWAVE MEDICAL, INC.82.67%6 689
ASAHI INTECC CO., LTD.-31.71%6 057